<!DOCTYPE html>

<html lang="en" data-theme="light">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Antiadrenergic Drugs - Essentials of Medical Pharmacology</title>

<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">

<link rel="stylesheet" href="../styles/main.css">

<script>
MathJax = {
    tex: {
        inlineMath: [['$', '$'], ['\\(', '\\)']],
        displayMath: [['$$', '$$'], ['\\[', '\\]']],
        processEscapes: true,
        processEnvironments: true
    },
    svg: { fontCache: 'global' },
    options: {
        skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
    }
};
</script>
<script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
<a href="#main-content" class="skip-link">Skip to main content</a>
<button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
    <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
    <span class="theme-toggle-icon dark-icon">üåô</span>
</button>

<div class="reading-progress-container">
    <div class="reading-progress-bar" id="reading-progress"></div>
</div>

<!-- Floating TOC -->
<nav class="floating-toc" id="floating-toc">
    <div class="floating-toc-header">
        <span>üìë</span> Table of Contents
    </div>
    <ul class="floating-toc-list">
        <li><a href="#alpha-blockers">Alpha Adrenergic Blockers</a></li>
        <li><a href="#alpha-drugs">Specific Alpha Blockers</a></li>
        <li><a href="#beta-blockers">Beta Adrenergic Blockers</a></li>
        <li><a href="#beta-drugs">Specific Beta Blockers</a></li>
        <li><a href="#combined-blockers">Combined $\alpha + \beta$ Blockers</a></li>
        <li><a href="#glaucoma">Drugs for Glaucoma</a></li>
        <li><a href="#problem-study">Problem Directed Study</a></li>
    </ul>
</nav>

<div class="page-wrapper">
    <div class="container">
        <article class="document-article">
            <header class="document-header">
                <div class="header-badge">
                    <span>üõ°Ô∏è</span>
                    <span>Topic 11</span>
                </div>
                <h1 class="document-title">Antiadrenergic Drugs and Drugs for Glaucoma</h1>
                <div class="title-meta">
                    <div class="meta-item">
                        <span>üìö</span>
                        <span>Drugs Acting on ANS</span>
                    </div>
                    <div class="meta-item">
                        <span>‚è±Ô∏è</span>
                        <span>45 min read</span>
                    </div>
                </div>
            </header>

            <main id="main-content" class="content-wrapper">
                <section class="content-section" id="introduction">
                    <div class="content-card">
                        <p>These drugs inhibit adrenergic responses mediated through the $\alpha$ or $\beta$ or both $\alpha$ and $\beta$ adrenergic receptors. They differ from "adrenergic neurone blocking drugs" (like reserpine or guanethidine) which act by interfering with storage or release of the adrenergic transmitter.</p>
                        
                        <div class="table-responsive">
                            <table class="comparison-table">
                                <thead>
                                    <tr>
                                        <th>Feature</th>
                                        <th>Antiadrenergic drugs</th>
                                        <th>Adrenergic neurone blocking drugs</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td><strong>Locus of action</strong></td>
                                        <td>Adrenergic receptors on effector cells</td>
                                        <td>Adrenergic neuronal membrane or contents</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Effect of nerve stimulation</strong></td>
                                        <td>Blocked</td>
                                        <td>Blocked</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Effect of injected Adr</strong></td>
                                        <td>Blocked</td>
                                        <td>Not blocked (may be potentiated)</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Specificity</strong></td>
                                        <td>Specific for $\alpha$ or $\beta$ receptors</td>
                                        <td>Sympathetic function decreased irrespective of receptor type</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>

                <!-- Section 1: Alpha Blockers -->
                <section class="content-section" id="alpha-blockers">
                    <div class="section-header">
                        <div class="section-number">01</div>
                        <h2 class="section-title">
                            <span class="title-icon">üõë</span>
                            $\alpha$ Adrenergic Blocking Drugs
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>These drugs inhibit adrenergic responses mediated through $\alpha$ adrenergic receptors without affecting those mediated through $\beta$ receptors.</p>

                        <h3>General Effects</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">1</span>
                                <span class="list-content"><strong>Blockade of vasoconstrictor $\alpha_1$ (and $\alpha_2$) receptors:</strong> Reduces peripheral resistance $\rightarrow$ pooling of blood in capacitance vessels $\rightarrow$ fall in BP and postural hypotension.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">2</span>
                                <span class="list-content"><strong>Vasomotor reversal of Dale:</strong> $\alpha$ blockers abolish the pressor action of Adrenaline (injected i.v.), which then produces only fall in BP due to $\beta_2$ mediated vasodilatation.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">3</span>
                                <span class="list-content"><strong>Reflex tachycardia:</strong> Due to fall in BP and blockade of presynaptic $\alpha_2$ receptors (which normally inhibit NA release).</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">4</span>
                                <span class="list-content"><strong>Sodium and water retention:</strong> Due to hypotension reducing renal blood flow and reflex increase in renin release.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">5</span>
                                <span class="list-content"><strong>Miosis and nasal stuffiness.</strong></span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">6</span>
                                <span class="list-content"><strong>Improvement of urine flow in BHP:</strong> By blocking $\alpha_1$ receptors in bladder trigone, prostate, and prostatic urethra.</span>
                            </li>
                        </ul>
                    </div>
                </section>

                <!-- Section 2: Specific Alpha Blockers -->
                <section class="content-section" id="alpha-drugs">
                    <div class="section-header">
                        <div class="section-number">02</div>
                        <h2 class="section-title">
                            <span class="title-icon">üíä</span>
                            Specific $\alpha$ Adrenergic Blockers
                        </h2>
                    </div>

                    <div class="content-card">
                        <h3>Phenoxybenzamine</h3>
                        <p>An irreversible (nonequilibrium) antagonist that forms strong covalent bonds with $\alpha$ receptors. Blockade lasts 3-4 days.</p>
                        <ul>
                            <li><strong>Action:</strong> Blocks $\alpha_1$ and $\alpha_2$. Causes postural hypotension and reflex tachycardia.</li>
                            <li><strong>Use:</strong> Primarily in <strong>Pheochromocytoma</strong> (preoperative preparation and inoperable cases).</li>
                            <li><strong>Side effects:</strong> Postural hypotension, palpitation, nasal blockage, inhibition of ejaculation.</li>
                        </ul>

                        <h3>Phentolamine</h3>
                        <p>A rapidly acting, short duration non-selective competitive $\alpha$ blocker. Causes marked tachycardia. Used for diagnosis of pheochromocytoma (rarely now) and control of hypertensive emergencies (e.g., clonidine withdrawal, cheese reaction).</p>

                        <h3>Selective $\alpha_1$ Blockers (Prazosin & Congeners)</h3>
                        <p>These drugs block $\alpha_1$ receptors selectively (ratio $\alpha_1:\alpha_2$ is 1000:1). They cause fall in BP with only mild tachycardia (no blockade of presynaptic $\alpha_2$).</p>

                        <div class="grid grid-2">
                            <div class="grid-item">
                                <h4>Prazosin</h4>
                                <p>First selective $\alpha_1$ blocker. Effective orally. Short $t_{1/2}$ (2-3 hrs).<br>
                                <strong>Adverse Effect:</strong> "First dose effect" (dizziness/fainting) - minimize by starting with low dose at bedtime.</p>
                            </div>
                            <div class="grid-item">
                                <h4>Terazosin & Doxazosin</h4>
                                <p>Longer acting congeners (once daily dosing). Used in HTN and BPH. May promote apoptosis in prostate.</p>
                            </div>
                        </div>

                        <h3>Uroselective $\alpha_1$ Blockers (For BPH)</h3>
                        <p>Benign Hypertrophy of Prostate (BPH) causes urinary obstruction. $\alpha_1$ blockers relax prostatic smooth muscle (dynamic obstruction).</p>
                        <ul class="enhanced-list">
                            <li class="list-item"><strong>Tamsulosin:</strong> Selective for $\alpha_{1A}$ subtype (predominant in prostate). Less vascular side effects. Risk of "Floppy iris syndrome" during cataract surgery.</li>
                            <li class="list-item"><strong>Silodosin:</strong> Highly selective $\alpha_{1A}$ blocker. Low incidence of hypotension but high incidence of retrograde ejaculation.</li>
                            <li class="list-item"><strong>Alfuzosin:</strong> Uroselective properties despite being non-subtype selective.</li>
                        </ul>

                        <h3>Yohimbine</h3>
                        <p>Selective $\alpha_2$ blocker. Increases central sympathetic outflow. No valid clinical indications currently.</p>

                        <div class="callout callout--warning">
                            <div class="callout-header">
                                <span class="callout-icon">‚ö†Ô∏è</span>
                                <h4 class="callout-title">Clinical Uses of $\alpha$ Blockers</h4>
                            </div>
                            <div class="callout-content">
                                <ol>
                                    <li><strong>Pheochromocytoma:</strong> Phenoxybenzamine (definitive/pre-op), Phentolamine (intra-op). NEVER use $\beta$ blockers without prior $\alpha$ blockade.</li>
                                    <li><strong>Hypertension:</strong> Prazosin class (not first line). Phentolamine for hypertensive crises.</li>
                                    <li><strong>Benign Hypertrophy of Prostate (BPH):</strong> Tamsulosin, Silodosin, Alfuzosin, Terazosin. Relieve voiding symptoms.</li>
                                    <li><strong>Peripheral Vascular Diseases:</strong> Limited utility (Raynaud's).</li>
                                </ol>
                            </div>
                        </div>
                    </div>
                </section>

                <!-- Section 3: Beta Blockers -->
                <section class="content-section" id="beta-blockers">
                    <div class="section-header">
                        <div class="section-number">03</div>
                        <h2 class="section-title">
                            <span class="title-icon">üõë</span>
                            $\beta$ Adrenergic Blocking Drugs
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>All $\beta$ blockers are competitive antagonists. <strong>Propranolol</strong> is the prototype.</p>

                        <h3>Pharmacological Actions (Propranolol)</h3>
                        <div class="grid grid-2">
                            <div class="grid-item">
                                <h4>1. Cardiovascular</h4>
                                <p><strong>Heart:</strong> Decreases HR, force of contraction, and cardiac output. Prolongs systole. Reduces cardiac work and $O_2$ consumption.<br>
                                <strong>Blood Vessels:</strong> Blocks $\beta_2$ vasodilatation $\rightarrow$ acute rise in TPR. Chronic use lowers BP in hypertensives.</p>
                            </div>
                            <div class="grid-item">
                                <h4>2. Respiratory</h4>
                                <p>Increases bronchial resistance ($\beta_2$ blockade). Can precipitate life-threatening asthma in susceptible individuals.</p>
                            </div>
                            <div class="grid-item">
                                <h4>3. Metabolic</h4>
                                <p>Blocks adrenergically induced lipolysis and glycogenolysis. Delays recovery from insulin hypoglycemia (masking of warning signs like tachycardia).</p>
                            </div>
                            <div class="grid-item">
                                <h4>4. Eye</h4>
                                <p>Reduces secretion of aqueous humor $\rightarrow$ lowers intraocular tension (IOP).</p>
                            </div>
                        </div>

                        <h3>Pharmacokinetics</h3>
                        <p>Propranolol is well absorbed but has low bioavailability due to <strong>high first pass metabolism</strong>. It is highly lipid soluble (crosses BBB). Metabolism is dependent on hepatic blood flow.</p>

                        <div class="callout callout--danger">
                            <div class="callout-header">
                                <span class="callout-icon">‚ö†Ô∏è</span>
                                <h4 class="callout-title">Adverse Effects & Contraindications</h4>
                            </div>
                            <div class="callout-content">
                                <ul>
                                    <li><strong>Precipitation of CHF:</strong> In patients with low cardiac reserve.</li>
                                    <li><strong>Bradycardia:</strong> Heart block, arrest.</li>
                                    <li><strong>Worsening of Asthma/COPD:</strong> Contraindicated in asthmatics.</li>
                                    <li><strong>Cold extremities:</strong> Worsening of peripheral vascular disease.</li>
                                    <li><strong>Metabolic:</strong> Hypoglycemia unawareness in diabetics; altered lipid profile (increased TG, decreased HDL).</li>
                                    <li><strong>Withdrawal:</strong> Sudden withdrawal can cause rebound hypertension, angina, or sudden death (upregulation of receptors).</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </section>

                <!-- Section 4: Specific Beta Blockers -->
                <section class="content-section" id="beta-drugs">
                    <div class="section-header">
                        <div class="section-number">04</div>
                        <h2 class="section-title">
                            <span class="title-icon">üíä</span>
                            Specific $\beta$ Blockers
                        </h2>
                    </div>

                    <div class="content-card">
                        <h3>Classification based on properties</h3>
                        
                        <div class="table-responsive">
                            <table class="comparison-table">
                                <thead>
                                    <tr>
                                        <th>Generation/Type</th>
                                        <th>Examples</th>
                                        <th>Features</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td><strong>Non-selective ($\beta_1 + \beta_2$)</strong></td>
                                        <td>Propranolol, Timolol, Sotalol, Nadolol</td>
                                        <td>Block both receptors. More likely to cause bronchoconstriction.</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Cardioselective ($\beta_1$)</strong></td>
                                        <td>Metoprolol, Atenolol, Acebutolol, Bisoprolol, Esmolol</td>
                                        <td>Relatively safer in asthma/diabetes (but not totally safe). Less likely to compromise peripheral circulation.</td>
                                    </tr>
                                    <tr>
                                        <td><strong>With Intrinsic Sympathomimetic Activity (ISA)</strong></td>
                                        <td>Pindolol, Acebutolol</td>
                                        <td>Partial agonists. Cause less bradycardia at rest.</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Third Generation (Vasodilatory)</strong></td>
                                        <td>Labetalol, Carvedilol ($\alpha$ blockade)<br>Nebivolol (NO release)<br>Celiprolol ($\beta_2$ agonism)</td>
                                        <td>Additional vasodilator properties.</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>Important Agents</h3>
                        <ul class="enhanced-list">
                            <li class="list-item"><strong>Atenolol:</strong> Cardioselective, water soluble (low CNS entry), long acting (OD dose). Common antihypertensive.</li>
                            <li class="list-item"><strong>Metoprolol:</strong> Cardioselective, lipid soluble. Used in HTN, Angina, CHF.</li>
                            <li class="list-item"><strong>Esmolol:</strong> Ultra-short acting ($t_{1/2}$ &lt; 10 min). Given i.v. for rapid control of ventricular rate in atrial fibrillation/flutter, or perioperative hypertension.</li>
                            <li class="list-item"><strong>Nebivolol:</strong> Highly selective $\beta_1$ blocker + NO-mediated vasodilatation. Good for HTN.</li>
                            <li class="list-item"><strong>Timolol:</strong> Non-selective. Widely used topically for glaucoma.</li>
                            <li class="list-item"><strong>Sotalol:</strong> Non-selective. Has Class III antiarrhythmic property ($K^+$ channel blockade).</li>
                        </ul>
                        
                        <h3>Therapeutic Uses of $\beta$ Blockers</h3>
                        <div class="grid grid-3">
                            <div class="grid-item">
                                <h4>Cardiovascular</h4>
                                <ul>
                                    <li>Hypertension</li>
                                    <li>Angina Pectoris</li>
                                    <li>Cardiac Arrhythmias</li>
                                    <li>MI (Secondary prophylaxis)</li>
                                    <li>CHF (Carvedilol, Metoprolol, Bisoprolol)</li>
                                </ul>
                            </div>
                            <div class="grid-item">
                                <h4>Non-Cardiovascular</h4>
                                <ul>
                                    <li>Glaucoma (Timolol)</li>
                                    <li>Thyrotoxicosis (Propranolol)</li>
                                    <li>Migraine Prophylaxis</li>
                                    <li>Essential Tremor</li>
                                    <li>Anxiety (Somatic symptoms)</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </section>

                <!-- Section 5: Combined Blockers -->
                <section class="content-section" id="combined-blockers">
                    <div class="section-header">
                        <div class="section-number">05</div>
                        <h2 class="section-title">
                            <span class="title-icon">üîó</span>
                            Combined $\alpha + \beta$ Blockers
                        </h2>
                    </div>

                    <div class="content-card">
                        <h3>Labetalol</h3>
                        <p>Blocks both $\alpha_1$ and $\beta$ receptors. $\beta$-blocking potency is ~3 times $\alpha$-blocking potency. Causes fall in BP by reducing PVR (vasodilation) without reflex tachycardia.</p>
                        <p><strong>Uses:</strong> Hypertensive emergencies (i.v.), Pheochromocytoma, Pregnancy induced hypertension.</p>

                        <h3>Carvedilol</h3>
                        <p>Blocks $\beta_1 + \beta_2 + \alpha_1$ receptors. Has antioxidant property.</p>
                        <p><strong>Major Use:</strong> Congestive Heart Failure (CHF). It retards progression and prolongs survival in stable mild-to-moderate CHF.</p>
                    </div>
                </section>

                <!-- Section 6: Glaucoma -->
                <section class="content-section" id="glaucoma">
                    <div class="section-header">
                        <div class="section-number">06</div>
                        <h2 class="section-title">
                            <span class="title-icon">üëÅÔ∏è</span>
                            Drugs for Glaucoma
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Glaucoma is a progressive optic nerve damage usually associated with raised intraocular tension (IOT). Goal: Lower IOT to target level.</p>

                        <h3>Mechanisms of IOT Reduction</h3>
                        <ol class="enhanced-list">
                            <li class="list-item"><strong>Reducing Aqueous Secretion:</strong> $\beta$ blockers, $\alpha_2$ agonists, Carbonic anhydrase inhibitors.</li>
                            <li class="list-item"><strong>Increasing Trabecular Outflow:</strong> Miotics (Pilocarpine).</li>
                            <li class="list-item"><strong>Increasing Uveoscleral Outflow:</strong> Prostaglandin analogues, $\alpha_2$ agonists.</li>
                        </ol>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../../../../../assets/images/image-20251214-8bd34912.jpeg" alt="Aqueous humour dynamics and sites of drug action" class="figure-image">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.1: Sites of action of antiglaucoma drugs.</figcaption>
                        </figure>

                        <h3>Drug Classes</h3>

                        <h4>1. Prostaglandin Analogues ($PGF_{2\alpha}$)</h4>
                        <p><strong>First choice drugs for open angle glaucoma.</strong></p>
                        <ul>
                            <li><strong>Latanoprost, Travoprost, Bimatoprost.</strong></li>
                            <li><strong>Mechanism:</strong> Increase uveoscleral outflow.</li>
                            <li><strong>Advantages:</strong> High efficacy, once daily dosing, no systemic side effects.</li>
                            <li><strong>Side effects:</strong> Iris pigmentation, eyelash growth, macular edema.</li>
                        </ul>

                        <h4>2. $\beta$ Adrenergic Blockers</h4>
                        <p><strong>Mechanism:</strong> Reduce aqueous formation (ciliary epithelium). No change in pupil size.</p>
                        <ul>
                            <li><strong>Timolol:</strong> Non-selective. Prototype.</li>
                            <li><strong>Betaxolol:</strong> $\beta_1$ selective. Safer in asthmatics but less efficacious.</li>
                            <li><strong>Side effects:</strong> Systemic absorption can cause bronchospasm, bradycardia.</li>
                        </ul>

                        <h4>3. $\alpha_2$ Adrenergic Agonists</h4>
                        <ul>
                            <li><strong>Brimonidine:</strong> Reduces aqueous formation + Increases uveoscleral outflow. Neuroprotective?</li>
                            <li><strong>Apraclonidine:</strong> Used for short term control of IOT spikes.</li>
                        </ul>

                        <h4>4. Carbonic Anhydrase Inhibitors (CAIs)</h4>
                        <ul>
                            <li><strong>Dorzolamide, Brinzolamide:</strong> Topical. Reduce bicarbonate formation in ciliary body $\rightarrow$ reduce aqueous secretion.</li>
                            <li><strong>Acetazolamide:</strong> Systemic (oral/i.v.). Used in acute cases/refractory cases. Systemic side effects limit long-term use.</li>
                        </ul>

                        <h4>5. Miotics (Cholinomimetics)</h4>
                        <ul>
                            <li><strong>Pilocarpine:</strong> Contraction of ciliary muscle $\rightarrow$ pulls scleral spur $\rightarrow$ opens trabecular meshwork.</li>
                            <li><strong>Use:</strong> Now 3rd line for open angle glaucoma. Definitive treatment for Angle Closure Glaucoma (to break pupillary block).</li>
                        </ul>

                        <div class="callout callout--danger">
                            <div class="callout-header">
                                <span class="callout-icon">üö®</span>
                                <h4 class="callout-title">Management of Acute Congestive Glaucoma</h4>
                            </div>
                            <div class="callout-content">
                                <p>Medical Emergency! Aim is to lower IOT rapidly to prevent vision loss.</p>
                                <ol>
                                    <li><strong>Hypertonic Mannitol (20%)</strong> or Glycerol i.v. (Osmotic dehydration of eye).</li>
                                    <li><strong>Acetazolamide</strong> 0.5 g i.v.</li>
                                    <li><strong>Miotic (Pilocarpine):</strong> Once IOT falls, to open the angle.</li>
                                    <li><strong>Timolol / Apraclonidine</strong> topical.</li>
                                    <li><strong>Definitive treatment:</strong> Laser Iridotomy.</li>
                                </ol>
                            </div>
                        </div>
                    </div>
                </section>

                <!-- Problem Directed Study -->
                <section class="content-section" id="problem-study">
                    <div class="section-header">
                        <div class="section-number">07</div>
                        <h2 class="section-title">
                            <span class="title-icon">üß©</span>
                            Problem Directed Study
                        </h2>
                    </div>

                    <div class="content-card">
                        <div class="callout callout--warning">
                            <div class="callout-header">
                                <span class="callout-icon">‚ùì</span>
                                <h4 class="callout-title">Case Study 10.1</h4>
                            </div>
                            <div class="callout-content">
                                <p>A 70-year-male with BPH was prescribed Tab. Terazosin 5 mg at bedtime. At night, he got up to pass urine, felt giddy and fainted. He recovered after being laid flat.</p>
                                <p><strong>(a) Rationale of terazosin?</strong> Blocks $\alpha_1$ receptors in bladder trigone/prostate $\rightarrow$ relaxes smooth muscle $\rightarrow$ improves flow.</p>
                                <p><strong>(b) Explanation for fainting?</strong> Postural hypotension ("First dose effect") due to blockade of vascular $\alpha_1$ receptors + pooling of blood.</p>
                                <p><strong>(c) Prevention?</strong> Start with low dose (1 mg), take while lying down in bed, educate patient about posture.</p>
                            </div>
                        </div>

                        <div class="callout callout--warning">
                            <div class="callout-header">
                                <span class="callout-icon">‚ùì</span>
                                <h4 class="callout-title">Case Study 10.2</h4>
                            </div>
                            <div class="callout-content">
                                <p>A 55-year-old lady with mild asthma used Timolol 0.5% eye drops for glaucoma. She developed severe breathlessness and wheezing (asthma attack).</p>
                                <p><strong>(a) Explanation?</strong> Systemic absorption of Timolol via nasolacrimal duct $\rightarrow$ blockade of bronchial $\beta_2$ receptors $\rightarrow$ bronchoconstriction.</p>
                                <p><strong>(b) Avoidance?</strong> Use cardioselective blocker (Betaxolol) or other class (Latanoprost). Compress inner canthus during instillation to reduce systemic absorption.</p>
                                <p><em>(See Appendix-1 for detailed solutions)</em></p>
                            </div>
                        </div>
                    </div>
                </section>

            </main>

            <nav class="document-nav">
                <div class="nav-container">
                    <a href="topic-10-adrenergic.html" class="nav-button nav-button--large nav-button--previous">
                        <div class="nav-label">Previous</div>
                        <div class="nav-title">Adrenergic Transmission</div>
                    </a>
                    
                    <div class="document-progress">
                        <div class="progress-indicator">
                            <span>11</span>
                            <span class="progress-separator">/</span>
                            <span>13</span>
                        </div>
                        <div class="progress-bar-container">
                            <div class="progress-bar-fill" style="width: 84.6%;"></div>
                        </div>
                        <div class="progress-label">Topic Progress</div>
                    </div>
                    
                    <a href="topic-12-histamine.html" class="nav-button nav-button--large nav-button--next">
                        <div class="nav-label">Next</div>
                        <div class="nav-title">Histamine & Antihistaminics</div>
                    </a>
                </div>
            </nav>
        </article>
    </div>
</div>

<!-- Lightbox Modal -->
<div class="lightbox-modal" id="lightbox-modal" role="dialog" aria-modal="true" aria-label="Image viewer" hidden>
    <div class="lightbox-backdrop"></div>
    <div class="lightbox-content">
        <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
        <img class="lightbox-image" src="" alt="">
        <p class="lightbox-caption"></p>
    </div>
</div>

<script src="../js/theme.js"></script>
<script src="../js/navigation.js"></script>
<script src="../js/interactions.js"></script>
</body>
</html>
